Spring Understanding the potential of generic substitution
|
|
- Kristopher McDowell
- 5 years ago
- Views:
Transcription
1 Spring 2014 Understanding the potential of generic substitution
2 Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming off patent has helped slow the increase in drug plan costs for plan sponsors. However, there are opportunities to further maximize savings, depending on the generic substitution rider that the plan has in place. Three generic substitution riders are available: 1. Generic substitution = No Q: What does this mean? A: There is no generic substitution rider on the policy. Q: What is paid for a prescription for a brand name product when a generic alternative is available? A: If the pharmacy dispenses the brand, it is reimbursed at the brand name price; if the pharmacy dispenses the generic, it is paid at the generic price. 2. Generic substitution = Yes Q: What does this mean? A: There is a generic substitution rider on the policy. Q: What is paid for a prescription for a brand name product when a generic alternative is available? A: If the pharmacy dispenses the brand, it is reimbursed at the generic price; if the pharmacy dispenses the generic, it is paid at the generic price. However, if the physician writes No Substitution on the prescription, and the pharmacy indicates this during the submission process, the brand is reimbursed at the brand drug price. 3. Generic substitution = Always Q: What does this mean? A: There is a mandatory generic substitution rider on the policy. Q: What is paid for a prescription for a brand name product when a generic alternative is available? A: Both brand and generic products are always reimbursed at the generic price; prescriptions where the physician writes No Substitution are reimbursed at the generic price. However, the plan member may pay the difference in price between the brand and generic and receive the brand name product. Private Plan Use of Generic Substitution While plan sponsors understand the concept of generic substitution, 27% of plan members are still covered by policies without any generic substitution rider (Figure 1). The increase in the Always generic substitution rider from 19% to 36% over the last year comes from groups who were previously using generic substitution and now want to ensure their savings are maximized. This trend is expected to continue. Perspective Spring
3 Figure 1: Cardholders with Generic Substitution Generic Substitution 100% 90% 80% 18.9% 27.8% 33.2% 35.5% 37.6% Percent of Cardholders (Lives Covered) 70% 60% 50% 40% 30% 50.0% 43.6% 38.6% 37.3% 35.5% 20% 10% 31.1% 28.6% 28.2% 27.2% 26.9% 0% Q4 December 31, Q1 March 31, Q2 June 30, Q3 September 30, Q4 December 31, 2013 ALWAYS Mandatory Generic Substitution AND No Substitution Prescriptions Paid at Generic Price YES Mandatory Generic Substitution with No Substitution Prescriptions Paid at Brand Price NO Mandatory Generic Substitution The Impact of the Generic Substitution Rider on Brand and Generic Drug Use TELUS Health classifies drugs as: single source includes brand name products which are patent protected; brand brand name product without patent protection and a generic alternative is available; or generic generic alternative product. Table 1: Percent of paid claims and eligible prescriptions: single-source, brand and generic drug products Percent of Paid Claims Percent of Eligible Prescription Cost Year YTD - October YTD - October Single 42.2% 39.9% 36.6% 35.0% 66.9% 66.9% 65.7% 66.1% Source Brand 7.0% 6.8% 7.0% 7.0% 5.2% 5.4% 6.0% 6.3% Generic 50.8% 53.3% 56.4% 58.0% 27.9% 27.7% 28.3% 27.7% The brand share of paid claims has remained relatively stable but there has been a substantial increase in the generic share of paid claims and a decline in paid claims for single source products - reflective of the loss of patent protection for high volume products and re-classification from single source to brand. Despite the decline in the proportion of claims for single-source products (now at 35% YTD October 2013), the proportion of eligible costs that single-source products represents remains at two-thirds (66.1% YTD October 2013). By considering the multisource environment, defined as brand + generic, the brand share of paid claims has remained relatively stable at approximately 11% across Canada (Figures 2 and 3). Perspective Spring
4 Figure 2: Brand share of multisource (brand + generic) paid claims 21.0% Brand Share of Paid Claims when Generic Alternative Is Available (Canada, Ontario, Quebec) Percent of Paid Claims (without Patent) and Generic Drug Products 19.0% 17.0% 15.0% 13.0% 11.0% 9.0% 7.0% 19.2% 19.2% 18.7% 18.9% 18.6% 18.2% 17.6% 17.2% 18.4% 18.9% 18.7% 18.8% 17.8% 17.4% 17.4% 16.9% 16.9% 16.7% 16.7% 16.5% 16.6% 16.6% 11.2% 11.2% 11.2% 11.5% 11.5% 11.7% 10.7% 10.9% 10.9% 11.0% 10.8% 10.9% 10.9% 10.7% 10.9% 10.9% 10.6% 10.7% 10.6% 10.6% 10.5% 10.3% 8.4% 8.5% 8.4% 8.3% 9.4% 9.6% 9.3% 9.3% 9.4% 9.2% 8.9% 9.0% 9.0% 9.0% 8.9% 9.0% 8.9% 9.0% 5.0% Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Canada Ontario Québec Figure 3: Brand share of multisource (brand + generic) paid claims Percent of Paid Claims for Brand (without Patent) and Generic Drug Products 13.0% 12.0% 11.0% 10.0% 9.0% 8.0% 7.0% 6.0% 5.0% Jan % Feb-12 Mar-12 Brand Share of Paid Claims when Generic Alternative Is Available (Canada, Western Canada, Atlantic Canada) 11.2% 11.2% 11.2% 10.7% 10.9% 10.9% 11.0% 10.9% 10.9% 10.7% 10.9% 10.9% 10.8% 10.6% 10.7% 10.6% 10.5% 10.6% 10.3% 9.3% 9.3% 8.7% 8.8% 7.5% 7.6% 7.6% 7.7% Apr-12 May-12 Jun % 7.2% 7.4% Jul-12 Aug-12 Sep % 11.5% 11.5% 9.4% 9.2% 9.1% 9.1% 9.1% 9.1% 9.1% 9.0% 8.8% 8.7% 8.8% 8.7% 8.7% 8.7% 8.6% 8.7% 8.6% 8.5% 7.6% 7.6% Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 Canada Western Canada Atlantic Canada 7.6% 7.6% 7.6% 7.7% 7.5% 7.5% 7.3% 7.4% 7.3% 7.2% 7.1% May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Perspective Spring
5 Use of No Substitution Prescriptions As noted above, the plan design for generic substitution comes into consideration when the physician indicates No Substitution on the patient s prescription. When we look further into the data, there has been an increase in the percentage of prescriptions written by the physician as No Substitution, a trend that is occurring in all regions. Nationally, the percentage of prescriptions written and dispensed as No Substitution has increased from 8.7% of brand name products in multisource product categories at the beginning of 2012 to 9.9% as of October 2013 (Figures 4 and 5). The most significant increases in No Substitution claims have occurred in Ontario (Figure 3) and Atlantic Canada (Figure 4). What can explain the apparent increase in No Substitution claims? There are several reasons why a physician might indicate No Substitution for keeping a plan member on a brand name drug when a generic exists: Allergies prescribers may want to keep a patient on a brand name drug due to allergies to the non-medicinal ingredients. Critical dose drugs 1 while Health Canada has stricter bioequivalence requirements, 2 there is anecdotal evidence (note: there is limited clinical study evidence) to demonstrate that a patient may have suboptimal outcomes when switched from the brand to generic or switched from one generic to another generic. Patient choice cards (Figure 6) these permit the patient to receive the brand name drug with the cost difference between generic drug cost and brand drug cost billed to the pharmaceutical company; note: this option is available to the patient without No Substitution written by the physician on the prescription, however, it would require the patient to request the brand from the pharmacy. Patient confusion the launch of more generic alternatives could lead to an increased risk of generic-to-generic switching if a patient switches pharmacies often or if the pharmacy changes the generic supplier and could result in patient confusion or a misunderstanding of their current drug therapies. A combination of any of the above. There likely has not been an increase in allergies, and Health Canada has standards in place to assess bioequivalence for drugs, including consideration of drug products that require more rigorous application of testing criteria including critical dose drugs, so neither of these offer a reasonable explanation for the increase in No Substitution. A more likely contributing factor is the increased availability and use of the patient choice cards that permit the patient to receive the brand name drug, with residual amounts being billed to the pharmaceutical manufacturer. The increase in these cards is driven by a number of factors that include the patent cliff and a paucity of blockbuster drugs to take over for the patent expiring blockbusters. The influx of these cards has led the Ontario Pharmacists Association to produce a guidance document for pharmacies that defines the three categories of cards (Figure 6). Perspective Spring
6 Figure 4: Brand name products dispensed because physician wrote No Substitution Percent of Paid Claims for Brand Products 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 11.2% 10.8% Brand Products Dispensed Because Physician Wrote No Substitution (Canada, Ontario, Quebec) 12.2% 11.9% 12.3% 12.1% 8.7% 8.8% 9.0% 9.0% 9.0% 9.1% 9.5% 9.6% 9.5% 14.5% 14.6% 14.6% 14.0% 14.1% 14.1% 14.2% 14.1% 13.7% 13.3% 13.1% 13.2% 12.8% 12.9% 12.8% 12.8% 7.9% 7.7% 7.6% 7.7% 7.5% 7.2% 7.3% 7.3% 6.9% 7.1% 7.1% 6.9% 10.6% 10.7% 10.5% 10.5% 10.6% 10.7% 10.2% 10.3% 9.9% 9.9% 10.0% 9.8% 9.9% 9.0% 8.7% 8.5% 8.2% 6.4% 6.5% 6.4% 6.4% 2.0% 0.0% Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Canada Ontario Québec Figure 5: Brand name products dispensed because physician wrote No Substitution 18.0% Brand Products Dispensed Because Physician Wrote No Substitution (Canada, Western Canada, Atlantic Canada) Percent of Paid Claims for Brand Products 16.0% 14.0% 12.0% 11.2% 11.2% 10.0% 8.7% 8.8% 9.0% 9.0% 9.0% 9.1% 9.5% 9.6% 9.5% 8.0% 6.0% 4.0% 6.2% 6.5% 12.2% 13.5% 13.9% 13.4% 13.3% 12.9% 13.1% 16.0% 16.0% 15.7% 14.8% 14.9% 14.9% 14.9% 14.6% 14.6% 14.3% 14.4% 14.4% 14.1% 10.5% 10.6% 10.7% 10.5% 10.6% 10.7% 10.2% 10.3% 9.9% 9.9% 9.8% 10.0% 9.9% 7.9% 8.0% 7.8% 7.9% 7.9% 7.9% 8.0% 7.7% 7.2% 7.2% 7.4% 7.5% 7.6% 7.6% 7.0% 6.9% 7.0% 7.0% 7.4% 7.2% 2.0% 0.0% Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Canada Western Canada Atlantic Canada Perspective Spring
7 Figure 6: Patient choice/drug loyalty drug cards (Source: Ontario Pharmacists Association) PATIENT CHOICE ( BRAND LOYALTY ) DRUG CARDS ** A PRIMER FOR PHARMACISTS ** SUBJECT: In the last few years, assorted types of cards to offset cost burden to patients have been introduced as defined below. This document focuses on the complexity of PATIENT CHOICE CARDS that are intended to cover the cost differential for patients between a specified branded drug product and its interchangeable generic counterpart. Types of Cards on the Market Drug Sample Cards Patient Assistance Cards Patient Choice Cards Also known as smart cards Also known as co-pay cards Also known as Brand Loyalty Cards or Manufacturer s Coupon Cards Intended to provide patients with a small introductory and (usually) complimentary supply of a new (trial) medication Intended to offset or reduce the out-ofpocket patient costs not covered by the patients public or private drug plan Claims are processed through a third party adjudicator on behalf of the manufacturer who absorbs the drug cost, mark-up and the pharmacy dispensing fee, up to a defined maximum Typically, the cards are available for high cost drugs, for which the out-of-pocket costs could present a significant financial challenge for the patient Claims are processed through a third party adjudicator on behalf of the brand name drug manufacturer who absorbs the costs up a defined maximum Designed to facilitate patient choice of medication therapy by eliminating the financial gap between generic and brand name medications Patients can choose to obtain or switch to the branded drug instead of its lower cost interchangeable brand, with little or no additional out-of-pocket expenditure Cards cover the difference in cost between what the drug plan will pay (typically the generic price) and the actual cost of the brand name drug, up to a defined maximum The Potential Savings Available from Maximizing Generic Substitution Plan sponsors, including plan sponsors without any generic substitution rider, have benefited from lower generic prices because of public mandatory generic substitution policies and the practice of pharmacists to preferentially dispense the generic product. Are there additional savings still available? The methodology for the analysis was to re-calculate the eligible ingredient cost substituting the generic unit cost for the brand unit cost, if higher, with the difference from the original eligible ingredient cost representing potential savings. Savings of up to 11% or up to $87.4 million (YTD October 2013) of the eligible ingredient cost for brand and generic drugs remain available to plan sponsors from increased use of generic alternatives. The most significant savings are in Quebec, with the elimination, in January 2013, of Best Available Price for 15 years (BAP 15), the Quebec policy through which the Quebec government reimbursed the brand name drugs for a 15-year period from the listing of the drug on the formulary, even if generic products become available. The elimination of this Quebec policy will continue to help plan sponsors capture the savings. While it will never be realistic to expect all available savings to be captured due to factors in the environment, there are savings available to plan sponsors that include a generic substitution rider on the policy. The highest level of savings is available to plan sponsors who include an ALWAYS generic substitution rider on the policy. Perspective Spring
8 Figure 7: Potential savings from maximizing generic substitution The Potential Savings Available from Maximizing Generic Substitution Percent of Eligible Ingredient Cost (Drug Cost + Markup) of Brand without Patent and Generic Alternatives 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 8.8% 10.8% 6.6% 9.2% 29.6% 28.9% 3.8% 0.0% 1.6% 1.3% 0.1% 0.4% 0.0% Canada Ontario Quebec Western Canada Atlantic Canada Territories (YTD - October) Summary Opportunities exist in all regions to increase the use of generic alternatives and decrease plan costs. A generic substitution rider on the policy is essential for taking the first step to capture savings from lower cost generic alternatives after the patent on the brand name product expires. But only with an always generic substitution rider on the policy can the increase of No Substitution prescriptions be managed and the savings from lower cost alternatives be maximized. Elaine McKenzie BSP, MBA Health Analytics Laura Blair Account Executive Laureen Rance BSc Pharm, PharmD, MSc Director, Centre of Excellence References 1 According to Health Canada, critical dose drugs are defined as drugs where comparatively small differences in dose or concentration lead to dose- and concentration-dependent, serious therapeutic failures and/or serious adverse drug reactions which may be persistent, irreversible, slowly reversible or life threatening, which could result in in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity or death. 2 Health Canada has two guidance documents: Conduct and Analysis of Comparative Bioavailability Studies and Comparative Bioavailability Standards: Formulations Used for Systemic Effects. The purpose of these documents is to update and consolidate 11 existing Health Canada documents related to the conduct and analysis of comparative bioavailability studies and the standards to be met in those studies in order to comply with relevant sections of the Food and Drug Regulations. These guidance documents also outline that drugs may have one or more characteristics that require modifications to the standards: modified-release dosage forms, drugs with serious toxicity within the normal dosage range, drugs exhibiting non-linear pharmacokinetics, drugs with a terminal elimination half-life of more than 24 hours, drugs with an important time of onset of effect or rate of absorption, critical dose drugs, combination products, drugs with highly variable pharmacokinetics, drugs with measurable endogenous levels, drugs for which pharmacodynamic studies are appropriate alternatives to comparative bioavailability studies of oral dosage formulations, drugs for which urine drug concentration data is used (available on the Internet at: Perspective Spring
9 Information for life TELUS Health is a leader in telehomecare, electronic medical and health records, consumer health, benefits management and pharmacy management. TELUS Health give health authorities, providers, physicians, patients and consumers the power to turn information into better health outcomes. For more information about TELUS Health, please visit telushealth.com. This article printed as part of Perspective - Spring 2014 issue. TELUS All rights reserved. Printed in Canada.
Interchangeable Drug Products - Additional Criteria
Interchangeable Drug Products - Additional Criteria Principle: Decisions respecting interchangeability and drug lists remain in the domain of the institution responsible for the costs of the product which
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationDRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects
1 2 3 DRAFT GUIDANCE DOCUMENT Comparative Bioavailability Standards: Formulations Used for Systemic Effects 4 This guidance document is being distributed for comment purposes only. 5 6 Published by authority
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationPLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
More informationKansas EMS Naloxone (Narcan) Administration
Kansas EMS Naloxone (Narcan) Administration Executive Summary Kansas Board of Emergency Medical Services August 217 The following pages denote an ongoing trending of naloxone administration by Kansas Emergency
More informationCost projections a single antiretroviral co-payment scheme for people with HIV in NSW. March 2013
Cost projections a single antiretroviral co-payment scheme for people with HIV in NSW March 2013 Background The first meeting of HIV Strategy Implementation Taskforce Committee endorsed a policy position
More informationJustifying New Oncology Pharmacist Positions
Faculty Disclosures Justifying New Oncology Pharmacist Positions I will not be discussing off-label uses of any medications I am on the speaker s bureau for Millenium Pharmaceuticals and am a paid consultant
More informationPost-marketing Surveillance of Generic Drug Usage and Substitution Patterns
Post-marketing Surveillance of Generic Drug Usage and Substitution Patterns U01FD004855 U.S. Food and Drug Administration (FDA) Office of Generic Drugs Ilene Harris, PharmD, PhD, IMPAQ (Presenter) Christine
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationPREFACE. Saskatchewan is participating in the Common Drug Review (CDR).
PREFACE OBJECTIVES The Drug Plan has been established to: provide coverage to Saskatchewan residents for quality pharmaceutical products of proven therapeutic effectiveness; reduce the direct cost of prescription
More informationPharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action
More informationAPPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS
APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 34 th EDITION THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT. U.S. DEPARTMENT
More informationRE: CONSULTATION ON DRAFT - DRUG AND NATURAL HEALTH PRODUCTS RECALL GUIDE
January 14, 2019 Health Products Compliance and Enforcement Unit Regulatory Operations and Regions Branch Health Canada By email to: hc.hpce-cpsal.sc@canada.ca RE: CONSULTATION ON DRAFT - DRUG AND NATURAL
More informationPublished by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
More informationFAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?
FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members
More informationAn Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center
An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center 1 TRICARE Eligible Beneficiaries Monthly Average, FY08 Retirees & Family
More informationBrand and Generic Drugs. Educational Objectives. Absorption
Peter J. Rice, PharmD, PhD Associate Professor of Pharmacology East Tennessee State University Educational Objectives Pharmacokinetic Processes Distribution Metabolism Excretion Similarities Active ingredient(s)
More informationTexas Vendor Drug Program Specialty Drug List Process. February 2019
Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed
More informationNebraska: What s Going On with the PDMP and HIE
Nebraska: What s Going On with the PDMP and HIE Kevin C. Borcher, PharmD PDMP Program Director NeHII, Inc. BJA PDMP North Regional Meeting October 16, 2018 Nebraska PDMP Legislative Summary LB 237 (2011)
More informationCarisoprodolol Quantity Limit Policy Impact Analysis
Carisoprodolol Quantity Limit Policy Impact Analysis Carisoprodolol (Soma ) is a skeletal muscle relaxant that has deemed by many to have limited effectiveness for the treatment of acute musculoskeletal
More informationBC PharmaCare Newsletter
BC PharmaCare ewsletter August 24, 2010 Edition 10-009 Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Pharmacy Services
More informationUpdate on Regulatory Changes. June 21, 2010
Update on Regulatory Changes June 21, 2010 1 OPA Update on Regulatory Changes June 17/10 - Meeting between Pharmacy & Ministry Pharmacy = OPA/CACDS/IPO Ministry = Brent Fraser & Pamela McDonald Items requiring
More informationOffice of the Auditor General Portage Avenue Winnipeg, Manitoba R3C 0C4
Office of the Auditor General 500-330 Portage Avenue Winnipeg, Manitoba R3C 0C4 April 2006 The Honourable George Hickes Speaker of the House Room 244, Legislative Building Winnipeg, Manitoba R3C 0V8 Dear
More informationFrequent Dispensing Frequently Asked Questions
What is the Frequent Dispensing Policy? The frequent dispensing policy covers a maximum number of dispensing fees for prescriptions filled daily or in 2 to 27 day supplies. The current policies regulating
More informationSleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
More informationCHILDHOOD ALLERGIES IN AMERICA
CHILDHOOD ALLERGIES IN AMERICA Severe Allergic Reactions Causing More Emergency Room Visits for U.S. Children PUBLISHED MARCH 13, 2018 ( 2 ) EXECUTIVE SUMMARY In this report, the Blue Cross Blue Shield
More informationBuprenorphine used in the treatment of opioid dependence: availability and price
7 th floor Wellington House 133 155 Waterloo Road London SE1 8UG 24 October 2018 Gateway number: L2018-443 Dear Director of Public Health, Buprenorphine used in the treatment of opioid dependence: availability
More informationCurators of the University of Missouri - Combined January 1, 2016 through December 31, 2016
Cost Management Report Delta Dental Network Coverage Network Utilization Discount Delta Dental PPO Network 28.3% 29.4% Delta Dental Premier Network 67.0% 12.0% Total 95.3% Savings Categories $ % of Net
More informationThe Impact of Generic Entry on the Utilization of the Ingredient
Patented Medicine Prices Review Board Conseil d examen du prix des médicaments brevetés The Impact of on the Utilization of the Ingredient September 2011 (Revised May 2012) National Prescription Drug Utilization
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationNovember 30, Dear Mr. Sprague: Re: Alberta Dental Fees
November 30, 2015 Mr. Bob Sprague, B.Sc., Pharmacy, MBA Director, Pharmaceuticals and Supplementary Health Benefits Branch Alberta Health Professional Services & Health Benefits Division PO Box 1360 Stn
More informationGeneric Medicines in Australia. Andrew McLachlan
Generic Medicines in Australia Andrew McLachlan andrewm@pharm.usyd.edu.au The aim of this presentation Overview of medicines policy and regulation in Australia Generic medicines in the Australia market
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationBC Methadone Maintenance System
BC Methadone Maintenance System Performance Measures 211/212 Office of the Provincial Health Officer With contributions by: Pharmaceutical Services Division & Population and Public Health Division British
More informationReducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital
Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell
More informationIn Australia, brand substitution of
Pharmaceutical brand substitution in Australia are there multiple switches per prescription? Abstract Background: In Australia, brand substitution by pharmacists has been possible since 1994. There is
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationAn Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
More informationCurators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report
Cost Management Report Program Design Specifics Standard Claims Management SAVINGS CATEGORIES SAVINGS RESULTS % OF NET SUBMITTED DOLLARS % OF PAID DOLLARS Deductible Applied $1,296,627 5.68% 9.78% Patient
More informationComplete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting
Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Eric B. Durbin, DrPH, MS, Director of Cancer Informatics Frances E. Ross, CTR,
More informationThe Impact of Generic Entry on the Utilization of the Ingredient
Patented Medicine Prices Review Board Conseil d examen du prix des médicaments brevetés The Impact of on the Utilization of the Ingredient September 2011 National Prescription Drug Utilization Information
More informationE & M Coding: Are You Leaving Money on the Exam Table?
ACS, PAHCOM & HNA Sponsored Practice Management Webcast Series March 2, 201 1 E & M Coding: Are You Leaving Money on the Exam Table? Introduction - Evaluation and Management Services (E&M Coding) are a
More informationQuit Rates of New York State Smokers
Quit Rates of New York State Smokers Sara M. Abrams, MPH Data Manager NYS Smokers Quitline Sara.Abrams@roswellpark.org September 6, 20 Presentation Outline Basic Quitline Service How Quit Rates are defined
More informationCARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:
RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription
More informationBisphosphonate Step Therapy Criteria
ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association Bisphosphonate Step Therapy Criteria Program may
More informationUnderstanding the Value of Generic Drugs
Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher
More informationUNDERSTANDING NEW HAMPSHIRE DENTAL CLAIMS DATA
UNDERSTANDING NEW HAMPSHIRE DENTAL CLAIMS DATA Quality Assurance and Preliminary Analysis Institute for Health Policy and Practice at UNH Abbott Willard, MS MPH Jo Porter, MPH Amy Costello, MPH Funding
More informationGuideline on the Regulation of Therapeutic Products in New Zealand
Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 January 2016 Section 1: Legislation Section summary This
More informationThe Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.
Lindsey Gilpin Chairman of the English Pharmacy Board Telephone: 020 7572 2519 Fax: 0207 572 2501 e-mail: howard.duff@rpsgb.org 25 th March 2010 Dear Sir/Madam, Consultation on the proposals to implement
More informationSouth Plains Emergency Medical Services, Inc. P.O. Box Lubbock, Texas 79453
South Plains Emergency Medical Services, Inc. P.O. Box 53597 Lubbock, Texas 79453 June 28, 2017 TO: SPEMS EMS Services SUBJECT: SPEMS PARAMEDIC PROTOCOL VARIANCE With the ongoing medication shortages,
More informationCrisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019
Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 20-Jan 21-Jan 22-Jan 23-Jan 24-Jan 25-Jan 26-Jan between January 14th - January 21st Please Note: The application deadline
More informationThe Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist
The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving
More information2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationSection: Claims Payment - Cognitive Services (PAS Policy Administered by Drug Plan and Extended Benefits Branch)
Section: Claims Payment - Cognitive Services (PAS Policy Administered by Drug Plan and Extended Benefits Branch) Reference Date of Issue June 3, 2009 Approved by Director of Operations PACT Partnership
More information- Description, Objectives, Operational Framework
2 1. CNCD - Overview (significance, causes, burden) 2. CDAP - Description, Objectives, Operational Framework 3. Research Findings of Study on CDAP - Research Objectives and Methodology - Limitations and
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More informationTamper-Resistant Properties of Drugs Regulations (TRPDR)
Tamper-Resistant Properties of Drugs Regulations (TRPDR) Cost Impact Analysis, 2019 PMPRB presentation to federal, provincial, and territorial public plan representatives on September 29, 2015. 1 Patented
More informationWelcome to your. Pharmacy Services Guide. Many of our stores are open 24 hours. To find one near you, visit or call SHOP CVS.
Welcome to your Many of our stores are open 24 hours. To find one near you, visit www.cvs.com or call 1-800-SHOP CVS. Pharmacy Services Guide 06530RXS09 - Item #456748 11/08 Supplying you with health information
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationOsteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage
Osteoporos Int (212) 23:1475 148 DOI 1.17/s198-11-1771-2 ORIGINAL ARTICLE Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage S. M. Cadarette & G. Carney
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationStatus of Opioid Treatment Efforts
Status of Opioid Treatment Efforts Health Reform Oversight Committee October 25, 2016 Harry Chen, MD, Commissioner The National Safety Council Categorized Vermont as One of Four States Making Progress
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationUT HEALTH S RESPONSE TO
UT HEALTH S RESPONSE TO THE OPIOID CRISIS Clinical Safety & Effectiveness Cohort # 21 Team 10 San Antonio THE TEAM Team Leaders: Fred Campbell, Rudy Garza, Samir Patel, Tyler Roe Team Members: Mysti Schott,
More informationDISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.
DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide
More informationMarketing on a Budget: Monthly quit & win challenges to drive quitline utilization. Presenters: John Atkinson & Elizabeth Harvey
Marketing on a Budget: Monthly quit & win challenges to drive quitline utilization Presenters: John Atkinson & Elizabeth Harvey WHAT IS THE FIRST WEEK CHALLENGE? Monthly campaign Register online or by
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationPositive Living Conference
Positive Living Conference Ft. Walton Beach, Thomas Liberti Chief, Bureau of HIV/AIDS Department of Health March 11, 2011 Tallahassee, 1 The Epidemic in, 2010 60% White Population: 18.8 million (4 th 16%
More informationJill Davidson CEO SHine SA. On Line Chlamydia Initiative
Jill Davidson CEO SHine SA On Line Chlamydia Initiative Sexual and Reproductive Health STI and HIV services Family planning services 9 clinic sites (including 1 women s prison/2 men s prison Workforce
More informationStrategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures
Modifying Co-Pay Structures Extended producer responsibility (EPR) is a policy approach in which the producer s responsibility for their product extends to the post-consumer management of that product
More informationObjectives. Quality Improvement: Learning Collaboratives & Pharmacist involvement
Quality Improvement: Learning Collaboratives & Pharmacist involvement Jennifer Lake, PharmD Ontario FHT Pharmacist Conf 10 Nov 2009 Objectives To review the goals and objectives of the Learning Collaboratives
More informationCost-Effectiveness of Lung Volume Reduction Surgery
Cost-Effectiveness of Lung Volume Reduction Surgery The Health Industry Forum October 24, 2007 - Washington DC The National Emphysema Treatment Trial National Emphysema Treatment Trial (NETT) Multicenter,
More informationGlobal Fund Approach to Health System Strengthening
Global Fund Approach to Health System Strengthening WHO Expert consultation on positive synergies between health systems and Global Health Initiatives Geneva, 29-30 May 2008 Dr Stefano Lazzari, Director
More informationOntario s Narcotics Strategy
Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action
More informationHuangdao People's Hospital
Table of contents 1. Background... 3 2. Integrated care pathway implementation... 6 (1) Workload indicators... 6 A. In eligible for care pathway... 6 B. Care pathway implementation... 7 (2) Outcome indicators...
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationArkansas Prescription Monitoring Program
Arkansas Prescription Monitoring Program ONE YEAR UPDATE Scott Pace, Pharm.D., Esq. Special Thanks Thanks to Denise Robertson at the Arkansas Department of Health for supplying the PMP data for this presentation
More information1. When are dispensers able to provide publicly funded naloxone emergency kits for Ontarians?
Ontario Public Drug Programs Division Ontario Naloxone Program for Pharmacies (ONPP) Frequently Asked Questions for Pharmacy Dispensers: Providing Publicly Funded Naloxone Kits and Claims Submission Using
More informationVaccine Starter Kit Program FAQs
Vaccine Starter Kit Program FAQs Program How does this program help Health Mart pharmacies provide vaccines for their customers? McKesson has designed a comprehensive program specifically for Health Mart
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationAn investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland s Health Service
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.21.3826.x An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland s Health
More informationHelp Wanted: MRO guidance in a THC world. RMAOEM April 6, 2018
Help Wanted: MRO guidance in a THC world RMAOEM April 6, 2018 Disclaimer This presentation should not be considered legal advice. History of legalized marijuana Drug screening process State and employer
More informationMedsCheck Reviews. Ontario
MedsCheck Reviews Ontario Contents Configuration... 1 Configuring Electronic Signatures... 1 Configuring Electronic MedsCheck Reviews... 2 Creating an ODB MedsCheck Consent Record... 3 Electronic MedsCheck
More informationGuidance Document. Comparative Bioavailability Standards: Formulations Used for System Effects
Guidance Document Comparative Bioavailability Standards: Formulations Used for System Effects Date Adopted: 2012/12/08 Revised Date: 2018/06/08 Effective Date: 2018/07/01 (for submissions filed on or after
More informationDate : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark
Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationOverview of Health IT in Massachusetts: Data to Inform and Improve Performance
Overview of Health IT in Massachusetts: Data to Inform and Improve Performance Office of Economic Analysis, Evaluation and Modeling & State HIE Program December 2011 Chartpack Team Office of Economic Analysis,
More informationThe Value of Walgreens
The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens
More informationPatients Perspective on TKI Generics in Haematology
Patients Perspective on TKI Generics in Haematology Šarūnas Narbutas President, POLA Milan, 14 June 2014 Outlook: TKI* Generics in the EU Market FIRST PATENT EXPIRATION EXCLUSIVITY EXPIRATION (EMA) INN
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationWhat you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh)
SEE IF YOU CAN BREAK FREE WITH NORTHERA (droxidopa) What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh) Use NORTHERA (droxidopa) is a prescription
More informationYour Prescription Card. Your guide for savings.
Kent State University P.O. Box 5190 Kent, OH 44242-0001 13578-00001_PM JOHN Q SAMPLE 2215 SANDERS RD NBT 2215-5 NORTHBROOK, IL 60062 Your Prescription Card. Your guide for savings. 00001 Dear Plan Member,
More informationInfluenza immunization timing
Influenza immunization timing Technical report March 2017 Public Health Ontario Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing
More informationImplementing Rapid Response Teams (RRT) National Call September 13, 2007
Implementing Rapid Response Teams (RRT) National Call September 13, 2007 Purpose By the end of this call, participants will have: Heard successes and learnings from Improvement Teams Updated information
More information18 Week 92% Open Pathway Recovery Plan and Backlog Clearance
18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted
More informationCOMPONENT TESTS OF CLASS I MILK AND FLUID MILK PRODUCTS PACIFIC NORTHWEST ORDER: 2008 AND 2013
UNITED STATES DEPARTMENT OF AGRICULTURE 1930-220th St. SE, Ste. 102 Agricultural Marketing Service 4835 E. Cactus Rd., Suite 365 Bothell, WA 98021 Dairy Programs Scottsdale, AZ 85254 Phone: (425) 487-6009
More informationPharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH
PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline
More information